🇺🇸 FDA
Patent

US 9301947

Ryanodine receptor inhibitors for treatment of T-cell mediated disorders

granted A61KA61K31/4025A61K31/4178

Quick answer

US patent 9301947 (Ryanodine receptor inhibitors for treatment of T-cell mediated disorders) held by The Regents of the University of California expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/4025, A61K31/4178, A61K31/422, A61K45/06